{"Abstract": [0], "Pancreatic": [1], "ductal": [2], "adenocarcinoma": [3], "(PDAC)": [4], "is": [5], "lethal": [6], "in": [7, 27, 50, 144, 234], "88%": [8], "of": [9, 32, 71, 80, 131, 147, 182, 238], "patients": [10, 113, 121, 206, 222, 240], "1": [11], ",": [12], "yet": [13], "harbours": [14], "mutation-derived": [15], "T": [16, 99, 142, 165, 176, 185, 200, 209, 225, 270], "cell": [17, 166, 271], "neoantigens": [18, 73], "that": [19, 174, 273], "are": [20], "suitable": [21], "for": [22], "vaccines": [23, 49], "2,3": [24], ".": [25], "Here": [26], "a": [28, 77, 81, 159, 189, 213, 254], "phase": [29], "I": [30], "trial": [31], "adjuvant": [33, 262], "autogene": [34, 67, 117, 264], "cevumeran,": [35, 118], "an": [36], "individualized": [37], "neoantigen": [38, 48], "vaccine": [39, 156, 190, 258], "based": [40], "on": [41], "uridine": [42], "mRNA\u2013lipoplex": [43], "nanoparticles,": [44], "we": [45, 60, 172], "synthesized": [46], "mRNA": [47, 257], "real": [51], "time": [52], "from": [53], "surgically": [54], "resected": [55], "PDAC": [56, 278], "tumours.": [57], "After": [58], "surgery,": [59], "sequentially": [61], "administered": [62, 127], "atezolizumab": [63, 115], "(an": [64], "anti-PD-L1": [65], "immunotherapy),": [66], "cevumeran": [68, 125, 265], "(a": [69], "maximum": [70], "20": [72], "per": [74], "patient)": [75], "and": [76, 91, 107, 116, 136, 169, 192, 248, 266], "modified": [78], "version": [79], "four-drug": [82], "chemotherapy": [83], "regimen": [84], "(mFOLFIRINOX,": [85], "comprising": [86], "folinic": [87], "acid,": [88], "fluorouracil,": [89], "irinotecan": [90], "oxaliplatin).": [92], "The": [93], "end": [94], "points": [95], "included": [96, 193], "vaccine-induced": [97], "neoantigen-specific": [98, 141, 196], "cells": [100, 143, 177, 210, 226], "by": [101], "high-threshold": [102], "assays,": [103, 171], "18-month": [104, 203], "recurrence-free": [105, 216], "survival": [106, 217], "oncologic": [108], "feasibility.": [109], "We": [110], "treated": [111], "16": [112, 148], "with": [114, 122, 150, 188, 207, 221, 276], "then": [119], "15": [120], "mFOLFIRINOX.": [123], "Autogene": [124], "was": [126, 134], "within": [128], "3": [129], "days": [130], "benchmarked": [132], "times,": [133], "tolerable": [135], "induced": [137], "de": [138], "novo": [139], "high-magnitude": [140], "8": [145], "out": [146], "patients,": [149], "half": [151], "targeting": [152], "more": [153], "than": [154], "one": [155], "neoantigen.": [157], "Using": [158], "new": [160], "mathematical": [161], "strategy": [162], "to": [163, 180, 253], "track": [164], "clones": [167], "(CloneTrack)": [168], "functional": [170], "found": [173], "vaccine-expanded": [175, 208, 224], "comprised": [178], "up": [179], "10%": [181], "all": [183], "blood": [184], "cells,": [186], "re-expanded": [187], "booster": [191], "long-lived": [194], "polyfunctional": [195], "effector": [197], "CD8": [198], "+": [199], "cells.": [201], "At": [202], "median": [204, 215], "follow-up,": [205], "(responders)": [211], "had": [212], "longer": [214], "(not": [218], "reached)": [219], "compared": [220], "without": [223], "(non-responders;": [227], "13.4": [228], "months,": [229], "P": [230], "=": [231], "0.003).": [232], "Differences": [233], "the": [235, 239], "immune": [236], "fitness": [237], "did": [241], "not": [242], "confound": [243], "this": [244], "correlation,": [245], "as": [246], "responders": [247], "non-responders": [249], "mounted": [250], "equivalent": [251], "immunity": [252], "concurrent": [255], "unrelated": [256], "against": [259], "SARS-CoV-2.": [260], "Thus,": [261], "atezolizumab,": [263], "mFOLFIRINOX": [267], "induces": [268], "substantial": [269], "activity": [272], "may": [274], "correlate": [275], "delayed": [277], "recurrence.": [279]}